Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs BDX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BDX Captures Overall Composite Edge (33.7 SELL vs 46.5 HOLD), While SYK Leads 4–2 on Growth & Valuation Pillars
BDX Overall Winner
6-Pillar Tally: SYK 4 – 2 BDX
Matrix Metrics: SYK 7 – 3 BDX
As of Nov 16, 2026, Becton, Dickinson and Co. (BDX) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (33.7/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while SYK wins 4–2 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus BDX at $216.52 (16.4x Forward P/E, 15.7% operating margin).
- Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. BDX 33.7/100 SELL), BDX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (15.7% vs. 24.0% operating margin) and revenue trajectory (-10.5% vs. +7.6% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SYK vs BDX
SYK
Stryker Corporation
$310.79
+0.37% 1D
Market Cap
$118.9B
TTM Revenue
$26.3B
Forward P/E
19.0x
Beta / 30D Vol
0.22β · 50% Vol
Unified Composite Score
46.5
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
BDX
Head-to-Head Winner
Becton, Dickinson and Co.
$216.52
-0.69% 1D
Market Cap
$58.8B
TTM Revenue
$19.5B
Forward P/E
16.4x
Beta / 30D Vol
0.16β · 25% Vol
Unified Composite Score
33.7
SELL
Tech 5.0
Fund 34.0
Flow 65.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (SYK 4 – 2 BDX)
1. Valuation Multiples
BDX
Forward P/E
19.0x
16.4x
Trailing P/E
33.3x
42.6x
PEG Ratio
1.54x
0.99x
EV / Revenue
5.0x
4.2x
2. Growth & Scale
SYK
Revenue Growth (YoY)
+7.6%
-10.5%
Earnings Growth (YoY)
-11.7%
+47.6%
TTM Revenue (USD)
$26.3B
$19.5B
Market Cap
$118.9B
$58.8B
3. Profitability & Quality
SYK
Gross Margin
65.7%
47.0%
Operating Margin
24.0%
15.7%
Net Profit Margin
13.8%
5.9%
Return on Equity (ROE)
16.0%
5.7%
4. Balance Sheet & Cash Flow
SYK
Cash Generation (TTM)
$4.57B
$3.71B
Cash Flow Margin
17.4%
19.1%
Net Cash / Leverage
$11.7B Net Debt (0.64x D/E)
$23.6B Net Debt (0.69x D/E)
Dividend Yield
1.10%
None (0.00%)
5. Options & Positioning
BDX
Options Structure Phase
SURGE
BREAKOUT
Current IV / %ile
28.1% (5th %ile)
20.7% (7th %ile)
Put/Call OI Skew
0.30x (Call-Skewed)
0.12x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
SYK
OpEx & R&D Intensity
41.7% of Rev ($11.0B)
31.3% of Rev ($6.09B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Concentrated Oligopoly Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SYK (7) vs BDX (3)| Institutional Metric | SYK | BDX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $118.9B | $58.8B | SYK | |
| Trailing P/E Ratio | 33.3x | 42.6x | SYK | |
| Forward P/E Ratio | 19.0x | 16.4x | BDX | |
| Revenue Growth (YoY) | +7.6% | -10.5% | SYK | |
| Operating Margin (TTM) | 24.0% | 15.7% | SYK | |
| Net Profit Margin | 13.8% | 5.9% | SYK | |
| Return on Equity (ROE) | 16.0% | 5.7% | SYK | |
| 52-Week Range Position | 36% ($267–$389) | 95% ($140–$220) | BDX | |
| Beta / 30D Volatility | 0.22β · 50% Vol | 0.16β · 25% Vol | BDX | |
| Unified Institutional Score | 46.5 / 100 (HOLD) | 33.7 / 100 (SELL) | SYK | |
| Trailing 12M Revenue (USD) | $26.3B | $19.5B | Scale | |
| Gross Profit Margin (TTM) | 65.7% | 47.0% | Quality | |
| PEG Ratio & EV / Revenue | 1.54x PEG · 5.0x EV/Rev | 0.99x PEG · 4.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $4.57B ($11.7B Net Debt (0.64x D/E)) | $3.71B ($23.6B Net Debt (0.69x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BDX +7.45 pp
3M Horizon
BDX +25.99 pp
6M Horizon
BDX +52.89 pp
1Y Horizon
BDX +28.93 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SYK Revenue | BDX Revenue | SYK Op. Margin | BDX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $13.6B | $16.0B | 18.7% | 9.4% | SYK |
| FY2019 | $14.9B | $17.3B | 18.2% | 10.2% | SYK |
| FY2020 | $14.3B | $16.1B | 15.5% | 5.7% | SYK |
| FY2021 | $17.1B | $19.1B | 15.1% | 11.8% | SYK |
| FY2022 | $18.4B | $18.9B | 15.4% | 12.1% | SYK |
| FY2023 | $20.5B | $19.4B | 19.0% | 10.9% | SYK |
| FY2024 | $22.6B | $20.2B | 16.3% | 11.9% | SYK |
| FY2025 | $25.1B | $21.8B | 19.5% | 11.8% | SYK |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SYK
SURGE
Current IV
28.1%
IV Percentile
5th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BDX
BREAKOUT
Current IV
20.7%
IV Percentile
7th %ile
Put/Call OI Skew
0.12x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact BDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SYK Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
41.7% of Rev ($11.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
BDX Moat Profile
Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
31.3% of Rev ($6.09B)
90D Engineering Disclosures
0 Published
Investor FAQ SYK vs BDX Key Questions & Quantitative Answers
As of Nov 16, 2026, Becton, Dickinson and Co. (BDX) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (33.7/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while SYK wins 4–2 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus BDX at $216.52 (16.4x Forward P/E, 15.7% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. BDX 33.7/100 SELL), BDX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (15.7% vs. 24.0% operating margin) and revenue trajectory (-10.5% vs. +7.6% YoY).
SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with BDX at -10.5% YoY revenue growth and +47.6% YoY earnings growth on $19.5B TTM revenue (47.0% gross margin, 15.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while BDX shifted +36.7%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 31.3% of Rev ($6.09B) (0 disclosures) for BDX.
BDX screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas BDX trades at 16.4x Forward P/E, 42.6x Trailing P/E, 0.99x PEG, and 4.2x EV/Revenue (19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus BDX (5.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, BDX carries 20.7% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.16β · 25% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BDX vs SYK · Reverse Pair
SYK vs MDT
· Sector Peer
SYK vs TMO
· Sector Peer
SYK vs BSX
· Sector Peer
BDX vs BAX
· Sector Peer
BDX vs APD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem